Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Virginia Erroi"'
Autor:
G. Fatti, Daniela Buccione, Franco Trevisani, Antonino Picciotto, Antonio Di Micoli, Patrizia Pontisso, Andrea Gallotta, Lilia Testa, Carlo Saitta, Valentina Fazio, Virginia Erroi, Marta Frigerio, Francoise Degos, V. Santi, Elisabetta Loggi, Alessandra Biasiolo, Giovanni Raimondo, Roberto Di Donato
Publikováno v:
Open Journal of Gastroenterology. :56-61
Aberrant Squamous Cell Carcinoma Antigen (SCCA) expression is an early hepatocarcinogenetic event and circulating SCCA-IgM complexes are elevated in most HCC patients. We evaluated whether serum SCCA-IgM levels can identify HCV +ve cirrhotic patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f2a84d1b807c3cfd9d99e58f5841bc8
https://doi.org/10.4236/ojgas.2012.22012
https://doi.org/10.4236/ojgas.2012.22012
Autor:
Antonio Daniele Pinna, Eleonora Bigonzi, Franco Trevisani, Virginia Erroi, Maria Cristina Morelli, Alessandro Cucchetti, Matteo Cescon, Giorgio Ercolani, S. Pellegrini
Publikováno v:
Digestive and Liver Disease. 44:523-529
Background The strategy of salvage transplantation for patients with hepatocellular carcinoma is based on the premise that tumour recurrence will be still transplantable at the time of recurrence. However, patients can not only present non-transplant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d7213a7ea7d1b4c1c455ae65380dfdf
https://doi.org/10.1016/j.dld.2012.01.018
https://doi.org/10.1016/j.dld.2012.01.018
Screening for primary liver cancer means surveillance for hepatocellular carcinoma (HCC), which is one of the most common cancers worldwide. Detection of HCC for curative treatment is increased by surveillance, but target population, optimal periodic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a73446906eb9e77273aea4d862ba5d9
http://hdl.handle.net/11585/375475
http://hdl.handle.net/11585/375475
Autor:
Edoardo G. Giannini, Vincenzo Savarino, Fabio Farinati, Francesca Ciccarese, Gianludovico Rapaccini, Mariella Di Marco, Luisa Benvegnu, Franco Borzio, Eugenio Caturelli, Maria Chiaramonte, The Italian Liver Cancer group [. . ., Virginia Erroi, Donatella Magalotti, Sabina Olmi, Emanuela Giampalma, Rita Golfieri, DOMENICALI, MARCO, ZOLI, MARCO, TREVISANI, FRANCO, BERNARDI, MAURO, BISELLI, MAURIZIO, CASSINI, ROMINA, CARACENI, PAOLO, CUCCHETTI, ALESSANDRO, GRAMENZI, ANNAGIULIA, RAVAIOLI, MATTEO, BALSAMO, CLAUDIA, MOSCONI, CRISTINA, RENZULLI, MATTEO, ROSELLI, PAMELA, RISSO, DAVIDE, BOSCO, GIOVANNA
Background: The role of clinically significant portal hypertension on the prognosis of cirrhotic patients undergoing hepatic resection for hepatocellular carcinoma (HCC) is debated. Aims: In this study, our aim was to assess the role of clinically si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07467fa2ca40b3d90aa9f87c7e2f3dc9
http://hdl.handle.net/11585/254695
http://hdl.handle.net/11585/254695
Autor:
Paolo Caraceni, Annagiulia Gramenzi, Luciano Attard, Fabio Tumietto, Leonardo Calza, Franco Trevisani, Pierluigi Viale, Michele Pavoni, Sara K. Tedeschi, Francesco Giuseppe Foschi, Alessandro Cucchetti, Gabriella Verucchi, Maria Chiara Cantarini, Virginia Erroi, Mauro Bernardi
Publikováno v:
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 45(6)
Background Although the number of human immunodeficiency virus-infected patients with chronic liver disease is increasing, the impact of human immunodeficiency virus on hepatocellular carcinoma outcome remains unclear. Aims This single centre study i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b2daccebb2a92afd6705083eb6ac58
https://pubmed.ncbi.nlm.nih.gov/23332770
https://pubmed.ncbi.nlm.nih.gov/23332770
The evaluated article assesses the effectiveness in clinical practice of surveillance with ultrasound (US) and α-fetoprotein (AFP) in patients at risk of developing hepatocellular carcinoma. After a median follow-up of 3.5 years, among the 442 enrol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a48764fa7ded2d2192da54b292fe51e
http://hdl.handle.net/11585/152223
http://hdl.handle.net/11585/152223
Autor:
M. Dall'Agata, Virginia Erroi, E.G. Giannini, Maria Martha Bernardi, Fabio Farinati, A. Gramenzi, Franco Trevisani, P. Del Poggio, Fabio Conti, Marta Frigerio, P. Andreone, Maurizio Biselli
Publikováno v:
Digestive and Liver Disease. 45:S43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f91486e99cc2deb7551de47876234998
https://doi.org/10.1016/s1590-8658(13)60131-0
https://doi.org/10.1016/s1590-8658(13)60131-0
Autor:
Alessandro Cucchetti, Francesca Garuti, Virginia Erroi, Federica Odaldi, Edoardo G. Giannini, Franco Trevisani
Publikováno v:
World Journal of Gastroenterology. 19:8808
Surveillance for hepatocellular carcinoma (HCC) is considered a standard of care for patients with chronic liver disease who are at risk of developing this malignancy. Several studies have shown that surveillance can improve the prognosis of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b1e73f26526e2d9f5b8931c54ffa63
https://doi.org/10.3748/wjg.v19.i47.8808
https://doi.org/10.3748/wjg.v19.i47.8808
Autor:
Sacco, Rodolfo, Mismas, Valeria, Granito, Alessandro, Musettini, Gianna, Masi, Gianluca, Caparello, Chiara, Vivaldi, Caterina, Felder, Martina, Bresci, Giampaolo, Fornaro, Lorenzo, Trevisani, Franco, Bernardi, Mauro, Bolondi, Luigi, Piscaglia, Fabio, Zoli, Marco, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Frigerio, Marta, Erroi, Virginia, Garuti, Francesca, Gramenzi, Annagiulia, Lenzi, Barbara, Magalotti, Donatella, Pecorelli, Anna, Venerandi, Laura, Farinati, Fabio, Giacomin, Anna, Vanin, Veronica, Pozzan, Caterina, Maddalo, Gemma, Ciccarese, Francesca, Del Poggio, Paolo, Olmi, Stefano, Di Marco, Mariella, Balsamo, Claudia, Di Nolfo, Maria Anna, Vavassori, Elena, Alberti, Alfredo, Benvegnã¹, Luisa, Gatta, Angelo, Gios, Maurizio, Golfieri, Rita, Giampalma, Emanuela, Mosconi, Cristina, Renzulli, Matteo, Rapaccini, Gian Lodovico, Bosco, Giulia, Caturelli, Eugenio, Roselli, Paola, Dellâisola, Serena, Ialungo, Anna Maria, Giannini, Edoardo G., Risso, Domenico, Marenco, Simona, Bruzzone, Linda, Savarino, Vincenzo, Picciotto, Antonino, Chiaramonte, Maria, Cabibbo, Giuseppe, Cammã , Calogero, Maida, Marcello, Di Martino, Arezia, Barcellona, Maria Rosa, Mega, Andrea, Gasbarrini, Antonio, Rinninella, Emanuele, Rotella, Virginia, Ginanni, Barbara, Foschi, Francesco Giuseppe, Lanzi, Arianna, Stefanini, Giuseppe Francesco, Dallâaglio, Anna Chiara, Cappa, Federica Mirici, Neri, Elga, Bassi, Paolo, Zanotti, Miriam, Missale, Gabriele, Biasini, Elisabetta, Porro, Emanuela, Morisco, Filomena, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadã , Laura, Gemini, Stefano, Borzio, Francesco, Virdone, Roberto
Background Lactate dehydrogenase (LDH) is a predictor of clinical outcome in hepatocellular carcinoma (HCC) patients. However, its predictive role in the clinical outcomes of sorafenib treatment has been poorly documented. The correlation between LDH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6bf596f5044f96cf28f22960292d6e7
http://hdl.handle.net/11577/3196003
http://hdl.handle.net/11577/3196003
Autor:
Cucchetti A., Trevisani F., Pecorelli A., Erroi V., Farinati F., Ciccarese F., Rapaccini G. L., Di Marco M., Caturelli E., Giannini E. G., Zoli M., Borzio F., Cabibbo G., Felder M., Gasbarrini A., Sacco R., Foschi F. G., Missale G., Morisco F., Baroni G. S., Virdone R., Bernardi M., Pinna A. D., Bolondi L., Biselli M., Caraceni P., Garuti F., Gramenzi A., Lenzi B., Magalotti D., Piscaglia F., Serra C., Ravaioli M., Venerandi L., Del Poggio P., Olmi S., Balsamo C., Di Nolfo M. A., Vavassori E., Alberti A., Benvegnu L., Gatta A., Giacomin A., Vanin V., Pozzan C., Maddalo G., Giampalma E., Cappelli A., Golfieri R., Mosconi C., Renzulli M., Dell'Isola S., Ialungo A. M., Roselli P., Risso D., Marenco S., Sammito G., Bruzzone L., Bosco G., Grieco A., Pompili M., Rinninella E., Siciliano M., Chiaramonte M., Guarino M., Camma C., Maida M., Di Martino A., Barcellona M. R., Schiada L., Gemini S., Biasini E., Porro E., del Ricambio M., Mismas V., Vivaldi C.
Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to lead-time bias.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16eb4b49aa2a9d942e11dee25f5a7504
http://hdl.handle.net/11588/585035
http://hdl.handle.net/11588/585035